FG Merger FGMCR Stock Analysis Climbs 534 Eyes on 081 20260519 Former Nigerian Power Minister Sentenced to 75 Years in Landmark Corruption Case OneIM OIMAW Stock Up 328 Key Resistance at 066 20260517 Rexford REXR Steady at 3572 Awaiting Next Catalyst 20260514 Taiwan Takes Center Stage in USChina Talks but Fades in XiPutin Dialogue Anterix ATEX Stock Today Rallies 361 Resistance at 6395 20260520 Credit Suisses Neelkanth Mishra Anticipates Repo Rate to Hit Decade Low Sees Market Pickup from December Voyager Technologies VOYG Q1 2026 Disappoints EPS 061 Below 058 Views Government Unveils Plan to Revamp Tax Administration for Seamless GST Implementation Intapp Highlights AIDriven Demand Growth as Celeste Platform Addresses Compliance Risks Bessent Predicts Substantial Disinflation Ahead as Warsh Set to Lead Fed Lowes Signals Consumer Caution as Home Improvement Demand Shifts Institutional Interest in Ford Stock Surges on Unusual LongTerm Call Options Activity Upstarts AIDriven Lending Model Evaluating the Potential for a LongTerm Breakthrough Dine Brands Q1 2026 Earnings EPS Beats Estimates by 53 Amid Operational Discipline HPE Q1 2026 Earnings EPS Surpasses Estimates by 93 Stock Edges Higher GAU Q1 2026 Earnings EPS Misses Estimates Slightly as Shares Edge Higher Lightwave Logic Inc LWLG Q3 2024 Earnings Continued RD Progress Amid PreRevenue Phase Stepan Company SCL Q1 2026 Earnings EPS Slightly Tops Estimates Revenue Not Disclosed Nexxen International Q3 2025 Earnings Strong EPS Surprise Amplifies Confidence in Profitability MITK Q1 2026 Earnings EPS Surpasses Estimates on Strong Operating Performance SMXT Q1 2026 Earnings Narrow Loss Highlights Cost Management Focus CRM Q1 2026 Earnings EPS Surges Past Estimates Stock Edges Lower White Mountains Insurance Group WTM Q2 2025 Earnings EPS Misses Estimates as Investment Gains Moderate ACNT Q1 2025 Earnings EPS Misses Estimates Amid Market Challenges Labour Youth Unemployment Review Suggests Need for System Reset on Benefits Policy Nuvalent Inc NUVL Q1 2026 Earnings Slightly Wider Loss No Revenue Yet as PreClinical Pipeline Progresses